The high public debt in the Americas has been analyzed to respond nearly three times more significantly in terms of national risk premium when fiscal deficits increase, compared to regions with lower debt. According to a report by the Bank for International Settlements (BIS), public debt in the Americas has reached its highest level in decades, with the debt-to-GDP ratio rising in 27 countries over the past ten years. Among these, about 40% saw an increase of more than 20 percentage points in their debt ratios, while approximately one-third experienced an increase of 10 to 20 percentage points. The interest costs of public debt have also shown an upward trend, with the BIS noting that there have often been instances where interest costs exceeded the growth rate of fiscal revenues. The analysis found that when fiscal deficits increase by 1% of GDP, the EMBI spread of economies with high public debt reacts nearly three times more than that of economies with low debt. The rise in risk premium is also linked to inflation expectations, with the BIS explaining that when national risk premiums rise, short-term inflation expectations may increase through currency depreciation and rising financial costs. The report emphasizes the need for a credible fiscal consolidation strategy and the protection of central bank independence for macroeconomic stability.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.












Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.


